

WEDNESDAY, APRIL 9

All times are in Pacific Time. Schedule is subject to change, and attendees will be notified via the HOPA mobile app.



APRIL 9-12 PORTLAND, OREGON

Wednesday Exhibit Halls Schedule:

Exhibit Hall A (Main Hall) open 5:30-7:30 PM; Exhibit Hall B (Poster Hall) open 5:30-7:30 PM.

MORNING												
7:00 AM	7:30 AM	8:00 AM	8:30 AM	9:00 AM	9:30 AM	10:00 AM	10:30 AM	11:00 AM	11:30 AM	12:00 PM	12:30 PM	
		8:00 AM-12:00 PM Pre-Conference Session: Talking Toxicities: Management Across the Continuum (4.0 ACPE) (A105) <i>Extra-fee event; pre-registration required.</i>									12:30-1:00 PM Meet & Greet with HOPA Board (OB LOBBY)	
7:00-8:00 AM Exploring Therapeutic Advances in Myelofibrosis and Key Considerations for Effective Management (1.0 ACPE) (B113-114) <i>Morning CE Symposium presented by PTCE.</i>		8:00 AM-12:00 PM Pre-Conference Session: Professional Association Leadership: Insights for Oncology Pharmacists (4.0 ACPE) (A106) <i>Extra-fee event; pre-registration required.</i>									12:00-1:00 PM EMERALD study update: Exploring the safety and efficacy data in patients with ER+/HER2-, ESR1-mutated mBC, including data from subgroup analyses (B113-114) <i>Afternoon Non-CE Symposium presented by Stemline.</i>	
7:00-8:00 AM Advancing Care in HER2-Negative Early Breast Cancer: Essential Insights and Best Practices for Oncology Pharmacists (1.0 ACPE) (B115-116) <i>Morning CE Symposium presented by PTCE.</i>											12:00-1:00 PM Getting Started and Transitioning to Outpatient Care for Patients with Relapsed or Refractory Multiple Myeloma (B115-116) <i>Afternoon Non-CE Symposium presented by Pfizer.</i>	
7:00-8:00 AM DLL3-Targeting BiTE Therapy in SCLC: A Pharmacist's Guide to Evidence and Integration (1.0 ACPE) (B117-119) <i>Morning CE Symposium presented by Peerview.</i>											12:00-1:00 PM FDA approved treatment combination in newly diagnosed multiple myeloma (B117-119) <i>Afternoon Non-CE Symposium presented by Sanofi.</i>	

AFTERNOON													
1:00 PM	1:30 PM	2:00 PM	2:30 PM	3:00 PM	3:30 PM	4:00 PM	4:30 PM	5:00 PM	5:30 PM	6:00 PM	6:30 PM		
1:15-2:00 PM President's Welcome Address & FHOPA Awards (OB 202-203)		2:00-2:10 PM Break (OB LOBBY)		3:20-4:20 PM Platform Research Presentations (1.0 ACPE) (OB 202-203)			4:20-4:30 PM Break (OB LOBBY)		5:30-7:30 PM Exhibit Hall A Open; Welcome Reception with Beverages and Appetizers; Industry Encore Poster Presentations				
				2:10-3:10 PM Integrating the Pharmacist Into Integrative Medicine (1.0 ACPE) (OB 201)					4:30-5:30 PM Antibody Drug Conjugates in Gynecologic Malignancies; Updates and Patient Management (1.0 ACPE) (OB 201)			6:00-7:00 PM Review of Evidence-Based Data for an Antibody-Drug Conjugate in Combination with a PD-1 Inhibitor for 1L LA/MUC (B113-114) <i>Evening Non-CE Symposium presented by Pfizer.</i>	
		2:10-3:10 PM The Hemophilia Eras Tour: A Blank Space for Emerging Therapies (1.0 BCOP) (OB 201)						4:30-5:30 PM Lattices & Ladders: Exploring Career Advancement Models for Oncology Pharmacists (1.0 ACPE) (OB 204)			6:00-7:00 PM Treatment of Adults with 2L + RAS wild-type, HER2 positive Metastatic Colorectal Cancer or BRAF V600E Mutated Metastatic Colorectal Cancer (PP-BRA-USA-0575) (B115-116) <i>Evening Non-CE Symposium presented by Pfizer.</i>		

KEY: OB = OREGON BALLROOM GENERAL SESSION EXHIBIT HALL A EXHIBIT HALL B COMMERCIALY SUPPORTED PROGRAMMING BCOP PRESENTATION PRACTICE MANAGEMENT RESEARCH BREAKOUT SESSION

THURSDAY, APRIL 10

All times are in Pacific Time. Schedule is subject to change, and attendees will be notified via the HOPA mobile app.



HOPA 2025

APRIL 9-12 PORTLAND, OREGON

Thursday Exhibit Halls Schedule:

Exhibit Hall A (Main Hall) open 11:50AM-2:15PM and 5:00PM-7:30PM; Exhibit Hall B (Poster Hall) 7:00AM-7:45PM.

MORNING											
7:00 AM	7:30 AM	8:00 AM	8:30 AM	9:00 AM	9:30 AM	10:00 AM	10:30 AM	11:00 AM	11:30 AM	12:00 PM	12:30 PM
	7:30-8:15 AM ☐ Grab & Go Attendee Breakfast (OB LOBBY)	8:15-9:30 AM Summitting the Peak: Navigating Updates and Challenges in Multiple Myeloma (1.25 ACPE) (OB 201)			9:30-9:40 AM ☐ Break (OB LOBBY)	9:40-10:40 AM A. Tarlatamab: Pioneering a New Frontier in Small Cell Lung Cancer Treatment B. Advances in Neoadjuvant Therapy for Melanoma (1.0 ACPE) (OB 201)				11:50 AM-2:15 PM ☐ Exhibit Hall A Open; Attendee Lunch	
7:00-8:00 AM Practical Management of AML with a BCL-2 Inhibitor (B113-114) <i>Morning Non-CE Symposium presented by Abbvie.</i>		8:15-9:30 AM Following the Trail of Blood: Utility of Circulating Tumor DNA (ctDNA) Across the Cancer Care Continuum (1.25 BCOP) (OB 202-203)			9:30-9:40 AM ☐ Break (OB LOBBY)	9:40-10:40 AM A. Navigating Immune Checkpoint Inhibitor Use in Solid Organ Transplantation B. Fairness, Access, and Representation at HOPA: Current and Future Directions (1.0 ACPE) (OB 202-203)		10:50 AM-12:00 PM Member Awards and Business Meeting (OB 202-203)		12:00-1:00 PM Maximizing Safety With Antibody-Drug Conjugates: Essential Practices for HER2, Trop-2, and HER3 Treatments (1.0 ACPE) (B113-114) <i>Afternoon CE Symposium presented by PTCE.</i>	
7:00-8:00 AM A Treatment Option for Certain Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) (B115-116) <i>Morning Non-CE Symposium presented by Merck.</i>		8:15-9:30 AM Training a Resilient Oncology Pharmacy Workforce: Strategies To Address Moral Distress, Compassion Fatigue, and Coping With Death and Dying in the Residency Model (1.25 ACPE) (OB 204)			9:30-9:40 AM ☐ Break (OB LOBBY)	9:40-10:10:40 AM A. Updates in the Management of Myelodysplastic Syndrome B. Managing Congenital Thrombotic Thrombocytopenia Purpura: Turning Tiny Platelets Into Big Wins (1.0 ACPE) (OB 204)				12:00-1:00 PM Exploring Oncolytic Viruses in Melanoma: Pharmacist-Led Approaches for Safe Integration (1.0 ACPE) (B115-116) <i>Afternoon CE Symposium presented by PTCE.</i>	
7:00-8:00 AM Explore the current data that could help you recognize/assess candidates for a CDK4 & 6 inhibitor (B117-119) <i>Morning Non-CE Symposium presented by Lilly.</i>					9:30-9:40 AM ☐ Break (OB LOBBY)					12:00-1:00 PM Transforming Lymphoma Treatment With Bispecific Antibodies: Practical Solutions for Oncology Pharmacy Teams (1.0 ACPE) (B117-119) <i>Afternoon CE Symposium presented by PTCE.</i>	
										12:00-1:00 PM Special Interest Groups (SIGs) in Exhibit Hall A Residency Program Directors; Industry Professionals; Specialty Pharmacy; New Practitioner & Trainee (Combined) (SIG Area Tables)	
										12:00-1:00 PM Special Interest Groups (SIGs) in "A" Rooms Pediatrics; Administration; Gynecologic Oncology; Ambulatory; EPIC (Beacon) Users	

KEY: OB = OREGON BALLROOM ☐ GENERAL SESSION █ EXHIBIT HALL A █ EXHIBIT HALL B █ COMMERCIALY SUPPORTED PROGRAMMING █ BCOP PRESENTATION █ PRACTICE MANAGEMENT █ RESEARCH █ BREAKOUT SESSION

See reverse side for afternoon sessions. →

THURSDAY, APRIL 10

All times are in Pacific Time. Schedule is subject to change, and attendees will be notified via the HOPA mobile app.



HOPA 2025

APRIL 9-12 PORTLAND, OREGON

Thursday Exhibit Halls Schedule:

Exhibit Hall A (Main Hall) open 11:50AM-2:15PM and 5:00PM-7:30PM; Exhibit Hall B (Poster Hall) 7:00AM-7:45PM.

AFTERNOON											
1:00 PM	1:30 PM	2:00 PM	2:30 PM	3:00 PM	3:30 PM	4:00 PM	4:30 PM	5:00 PM	5:30 PM	6:00 PM	6:30 PM
11:50 AM-2:15 PM ☰ Exhibit Hall A Open; Attendee Lunch				2:45-2:55 PM ☰ Break (OB LOBBY)		3:30-3:45 PM ☰ Break (OB LOBBY)		3:45-5:00 PM Menopausal Side Effects of Hormone Therapy in Breast Cancer: Novel Therapies and Real-World Experiences (1.25 ACPE) (OB 201)		5:00-7:30 PM ☰ Exhibit Hall A Open with E-Poster Reception 5:15-7:45 PM Exhibit Hall B/Poster Hall: E-Posters for Completed Research, Late Breaking Research and Top Trainee Research	
1:00-2:15 PM Annual Advocacy Update (OB 202-203)			2:30-3:30 PM Navigating Barriers to Treatment and Pain Relief for Sickle Cell Disease Patients (1.0 ACPE) (OB 201)			3:45-5:00 PM Targeting EGFR-Mutant NSCLC: Which Road To Take? (1.25 ACPE) (OB 204)				6:00-7:00 PM Key Considerations for Operationalizing Bispecifics in Relapsed or Refractory Multiple Myeloma (B113-114) <i>Evening Non-CE Symposium presented by Johnson & Johnson.</i>	
		2:30-3:30 PM Captivating Updates in Chronic Lymphocytic Leukemia: A Shifting Paradigm (1.0 BCOP) (OB 202-203)				3:45-4:45 PM Acutely Aware of the Advancements Needed in Acute Graft-versus-Host Disease (aGVHD) Management (ASTCT Encore) (1.0 BCOP) (OB 202-203)				6:00-7:00 PM Alternative Routes of Administration: Advancing Oncology Care with Subcutaneous Immunotherapy (B115-116) <i>Evening Non-CE Symposium presented by BMS.</i>	
		2:30-3:30 PM Updates and Future Directions in the Treatment of HR-Positive, HER2-Negative Metastatic Breast Cancer (1.0 ACPE) (OB 204)									

KEY: OB = OREGON BALLROOM GENERAL SESSION EXHIBIT HALL A EXHIBIT HALL B COMMERCIALLY SUPPORTED PROGRAMMING BCOP PRESENTATION PRACTICE MANAGEMENT RESEARCH BREAKOUT SESSION

FRIDAY, APRIL 11

All times are in Pacific Time. Schedule is subject to change, and attendees will be notified via the HOPA mobile app.



HOPA 2025

APRIL 9-12 PORTLAND, OREGON

Friday Exhibit Halls Schedule:

Exhibit Hall A (Main Hall) open 11:50AM-2:15PM; Exhibit Hall B (Poster Hall) 7:00AM-2:00PM.

MORNING											
7:00 AM	7:30 AM	8:00 AM	8:30 AM	9:00 AM	9:30 AM	10:00 AM	10:30 AM	11:00 AM	11:30 AM	12:00 PM	12:30 PM
	7:30-8:15 AM ☑ Grab & Go Attendee Breakfast (OB LOBBY)				9:30-9:40 AM ☑ Break (OB LOBBY)					11:50 AM-2:00 PM ☑ Exhibit Hall A Open; Attendee Lunch	
7:00-8:00 AM Advancing Care in Metastatic Prostate Cancer Care: Emerging Combination Therapies and Patient-Centered Strategies (B113-114) <i>Morning Non-CE Symposium presented by PTCE.</i>		8:15-9:30 AM Pipeline To Progress: Novel Agents for Solid Tumors (1.25 ACPE) (OB 201)			9:30-9:40 AM ☑ Break (OB LOBBY)	9:40-10:40 AM A. 505(b)(2) Drugs: New Chaos for Infusion Centers B. Transforming Excess Into Access: Creation of an Oral Chemotherapy Repository Program (1.0 ACPE) (OB 201)		10:40-10:50 AM ☑ Break (OB LOBBY)	10:50-11:50 AM John G. Kuhn Keynote Address: Without Borders: the Global Face of Cancer Speaker: Carolyn Taylor, Founder/Executive Director, Global Focus on Cancer (OB 202-203)	12:00-1:00 PM Exhibit Hall B/Poster Hall: Trainee Research Poster Presentations - Even Numbers	12:00-1:00 PM Breakthrough Innovation: The First and Only Bispecific T-cell Engager (BiTE®) Therapy for 2L+ Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (B113-114) <i>Afternoon Non-CE Symposium presented by Amgen.</i>
7:00-8:00 AM Adapting to Advances in EGFR-Positive Non-Small Cell Lung Cancer Treatment: Critical Insights for Oncology Pharmacists (B115-116) <i>Morning Non-CE Symposium presented by PTCE.</i>		8:15-9:30 AM Let's Be Real: Challenging, Honest Conversations With Patients (1.25 BCOP) (OB 202-203)			9:30-9:40 AM ☑ Break (OB LOBBY)	9:40-10:40 AM A. Turning the Tide: Immunotherapy's Promise in the Fight Against Merkel Cell Carcinoma B. New Updates Integrating Checkpoint Inhibitors Into the Management of Colorectal Cancer (1.0 ACPE) (OB 202-203)				12:00-1:00 PM A Unique PD-1 Inhibitor for the 1L Treatment of Adult Patients with ESCC and GC/GEJC (B115-116) <i>Afternoon Non-CE Symposium presented by BeiGene.</i>	
7:00-8:00 AM Innovative Approaches and Critical Insights in the Management of Newly Diagnosed Multiple Myeloma (B117-119) <i>Morning Non-CE Symposium presented by PTCE.</i>		8:15-9:15 AM Maintenance Therapy in AML: A Trailblazing Slam Dunk, or a Flagrant Foul (1.25 ACPE) (OB 204)			9:30-9:40 AM ☑ Break (OB LOBBY)	9:40-10:40 AM A. CMV You Never: Practical Issues Regarding Cytomegalovirus Prophylaxis/Management in the HSCT Population B. Use of Psychedelic Medicines in Oncology and Palliative care: An Out of This World Lecture (1.0 ACPE) (OB204)				12:00-1:00 PM LONSURF® + bevacizumab for the Treatment of 3L Metastatic Colorectal Cancer (B117-119) <i>Afternoon Non-CE Symposium presented by Taiho.</i>	
7:00-8:00 AM ☑ Mentorship Breakfast (Invitation Only) (HYATT - WILLIAMETTE 2)										12:00-1:00 PM Special Interest Groups (SIGs) in Exhibit Hall A Classical Hematology; Cerner Oncology Users; Geriatrics; Residency Program Directors; New Practitioner & Trainee (Combined)	
										12:00-1:00 PM Special Interest Groups (SIGs) in "A" Rooms Investigational Drug Services; Academia; Breast Cancer; Transplant and Cellular Therapy; Precision Health in Oncology	

KEY: OB = OREGON BALLROOM GENERAL SESSION EXHIBIT HALL A EXHIBIT HALL B COMMERCIALLY SUPPORTED PROGRAMMING BCOP PRESENTATION PRACTICE MANAGEMENT RESEARCH BREAKOUT SESSION

See reverse side for afternoon sessions. →

FRIDAY, APRIL 11

All times are in Pacific Time. Schedule is subject to change, and attendees will be notified via the HOPA mobile app.



HOPA 2025

APRIL 9-12 PORTLAND, OREGON

Friday Exhibit Halls Schedule:

Exhibit Hall A (Main Hall) open 11:50AM-2:15PM; Exhibit Hall B (Poster Hall) 7:00AM-2:00PM.

AFTERNOON												
1:00 PM	1:30 PM	2:00 PM	2:30 PM	3:00 PM	3:30 PM	4:00 PM	4:30 PM	5:00 PM	5:30 PM	6:00 PM	6:30 PM	
11:50 AM-2:00 PM Exhibit Hall A Open; Attendee Lunch		2:00-2:45 PM Incoming President's Address & Board Awards (OB 202-203)		2:45-2:55 PM Break (OB LOBBY)	2:55-3:55 PM The BIG Idea Pitch Session (OB 202-203)			5:45-7:45 PM Closing Reception: Celebrate HOPA in Portland Style (OB LOBBY AND NORTH PLAZA)				
					4:05-5:20 PM It's About Time: Cellular Therapy Primer for Solid Tumorsy (1.25 BCOP) (OB 202-203)			5:30-6:30 PM Pharmacist Perspectives: Navigating BCMA-Directed Therapies in Multiple Myeloma (B113-114) <i>Evening Non-CE Symposium presented by Medscape.</i>				
					4:05-5:20 PM Unveiling the Future: A Discussion on AI Applications in Oncology Pharmacy (1.25 ACPE) (OB 201)							
					4:05-5:20 PM When Vitamin A and Heavy Metal Doesn't Cut It: Anthracyclines vs. Targeted Therapy for High-Risk APL (1.25 ACPE) (OB 204)							

KEY: OB = OREGON BALLROOM GENERAL SESSION EXHIBIT HALL A EXHIBIT HALL B COMMERCIALLY SUPPORTED PROGRAMMING BCOP PRESENTATION PRACTICE MANAGEMENT RESEARCH BREAKOUT SESSION

SATURDAY, APRIL 12

All times are in Pacific Time. Schedule is subject to change, and attendees will be notified via the HOPA mobile app.



HOPA 2025

APRIL 9-12 PORTLAND, OREGON

Exhibit Halls are closed on Saturday.

MORNING											
7:00 AM	7:30 AM	8:00 AM	8:30 AM	9:00 AM	9:30 AM	10:00 AM	10:30 AM	11:00 AM	11:30 AM	12:00 PM	12:30 PM
	7:30-8:15 AM Grab & Go Attendee Breakfast (OB LOBBY)				9:30-9:40 AM Break (OB LOBBY)						
7:00-8:00 AM Expanding Access to Antibody-Based Regimens in Relapsed/Refractory Multiple Myeloma (1.0 ACPE) (B113-114) <i>Morning CE Symposium presented by PTCE.</i>		8:15-9:15 AM Challenging Cases in Pediatrics (1.0 ACPE) (OB 201)				9:45-10:45 AM The Crossroad of Social Determinants of Health and Inequalities in Hematologic Malignancies (1.0 ACPE) (OB 201)			11:00-12:00 PM A Treatment Option for Patients With Primary Advanced or Recurrent Endometrial Cancer (B113-114) <i>Afternoon Non-CE Symposium presented by GSK.</i>		
7:00-8:00 AM Tracking a Moving Target in HR+ Metastatic Breast Cancer: Innovative Oral Therapies and Evolving Strategies (1.0 ACPE) (B115-116) <i>Morning CE Symposium presented by PTCE.</i>		8:15-9:30 AM Cracking the Code: Application of Pharmacogenomics in Hematology/Oncology Practice (1.25 BCOP) (OB 202-203)				9:45-10:45 AM Roles of Pharmacy Technicians in Ambulatory Oncology Clinics (1.0 ACPE) (OB 204)			11:00-12:00 PM Columvi: The First FDA-Approved Fixed-Duration Bispecific Antibody for 3L+ Diffuse Large B-Cell Lymphoma (B115-116) <i>Afternoon Non-CE Symposium presented by Genentech.</i>		

KEY: OB = OREGON BALLROOM ■ GENERAL SESSION ■ EXHIBIT HALL A ■ EXHIBIT HALL B ■ COMMERCIALLY SUPPORTED PROGRAMMING ■ BCOP PRESENTATION ■ PRACTICE MANAGEMENT ■ RESEARCH ■ BREAKOUT SESSION



Talking Toxicities: Management Across the Continuum Pre-Conference

Association Leadership: Insights for Oncology Pharmacists Pre-Conference

Quiet Room

Sponsored Symposia



Registration Hours
 Tuesday: 2:00-5:30 PM
 Wednesday-Friday: 7:00 AM-5:30 PM
 Saturday: 7:00-10:00 AM

Exhibit Hall A (Main Hall) Hours
 Wednesday: 5:30-7:30 PM
 Thursday: 11:50 AM-2:15PM; 5:00-7:30 PM
 Friday: 11:50 AM-2:00 PM

Exhibit Hall B (Poster Hall) Hours
 Wednesday: 5:30-7:30 PM
 Thursday: 7:00 AM-7:45 PM
 Friday 7:00 AM-2:00 PM